Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Yumuk, Perran F ^a   Turhal, Nazim S ^a   Gumus, Mahmut ^b   Hatabay, Nilgun F ^c   Turken, Orhan ^d   Ozkan, Alper ^b   Salepci, Taflan ^b   Aliustaoglu, Mehmet ^b   Ahiskali, Rengin ^e  

^a Division of Medical Oncology   (Turkey)

^b Lutfi Kirdar Training and Research Hospital   (Turkey)

^c Cardiovascular Surgery Clinic   (Turkey)

^d GULHANE SCHOOL OF MEDICINE   (Turkey)

^e MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE METASTASIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTPATIENT; PREMEDICATION; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; VOMITING; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 13144274588     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-5-10     Document Type: Article

References (27)

1. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993, 11:1866-1872.
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909.
3. Billingham LJ, Cullen MH: The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001, 12:1671-1675.
4. Ramanathan RK, Belani CP: Chemotherapy for non-small cell lung cancer: Past, present and future. Semin Oncol 1997, 24 1-15.
5. Bonomi P, Kim KM, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000, 18:623-631.
6. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A, Rosell R: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 1999, 17:12-18.
7. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993, 85:388-394.
8. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993, 85:384-388.
9. Miller KD, Sweeney CJ, Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:195-206.
10. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346:92-98.
11. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999, 17:409-422.
12. National Cancer Institute: Common Toxicity Criteria. Bethesda: MD, 1988.
13. Miller AB, Hogestraeten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207-214.
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
15. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
16. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001, 19:3210-3218.
17. Alvarez A, Mickiewicz, Brosio C, Giglio R, Cinat G, Suarez A: Weekly taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule. In Proceedings of the American Society of Clinical Oncology: 16-19 May 1998; California. Edited by Michael C. Perry: W.B. Saunders; 1998:188a.
18. Akerley W: Paclitaxel in advanced non-small-cell lung cancer: An alternative highdose weekly schedule. Chest 2000, Suppl:152-155.
19. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998, 16 153-158.
20. Akerley W, Herndon J, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR: Weekly, high dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003, 97:2480-2486.
21. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM: Multicenter, randomized trial for IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003, 21:2933-2939.
22. Belani CP: Weekly paclitaxel and carboplatin in non-small cell lung cancer. Lung Cancer 2000, Suppl 2:128-129.
23. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002, 20:1335-1343.
24. Smith IE, O'Brien MER, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001, 19:1336-1343.
25. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ: Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999, 17 676-684.
26. Kearns C, Egorin M: Considerations regarding the less-than expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997, Suppl 2:91-96.
27. Belani CP: Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest 2000, Suppl:144-151.